Rolf Burghaus

1.2k total citations
33 papers, 867 citations indexed

About

Rolf Burghaus is a scholar working on Cardiology and Cardiovascular Medicine, Pharmacology and Statistics and Probability. According to data from OpenAlex, Rolf Burghaus has authored 33 papers receiving a total of 867 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Cardiology and Cardiovascular Medicine, 7 papers in Pharmacology and 7 papers in Statistics and Probability. Recurrent topics in Rolf Burghaus's work include Pharmacogenetics and Drug Metabolism (7 papers), Statistical Methods in Clinical Trials (5 papers) and Pharmaceutical studies and practices (5 papers). Rolf Burghaus is often cited by papers focused on Pharmacogenetics and Drug Metabolism (7 papers), Statistical Methods in Clinical Trials (5 papers) and Pharmaceutical studies and practices (5 papers). Rolf Burghaus collaborates with scholars based in Germany, United States and France. Rolf Burghaus's co-authors include Jörg Lippert, Stefan Willmann, Katrin Coboeken, Kirstin Thelen, Jennifer Dressman, Alexander Staab, Sebastian Frechen, S. Y. Amy Cheung, Norbert Frey and Bengt Hamrén and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Rolf Burghaus

30 papers receiving 850 citations

Peers

Rolf Burghaus
Marylore Chenel France
Kaori Kadoyama Japan
Daniel F. B. Wright New Zealand
Hao Zhu United States
DR Mould United States
Jakob Ribbing Sweden
Nidal Al‐Huniti United States
Vangelis Karalis Greece
MO Karlsson Sweden
Satjit Brar United States
Marylore Chenel France
Rolf Burghaus
Citations per year, relative to Rolf Burghaus Rolf Burghaus (= 1×) peers Marylore Chenel

Countries citing papers authored by Rolf Burghaus

Since Specialization
Citations

This map shows the geographic impact of Rolf Burghaus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rolf Burghaus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rolf Burghaus more than expected).

Fields of papers citing papers by Rolf Burghaus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rolf Burghaus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rolf Burghaus. The network helps show where Rolf Burghaus may publish in the future.

Co-authorship network of co-authors of Rolf Burghaus

This figure shows the co-authorship network connecting the top 25 collaborators of Rolf Burghaus. A scholar is included among the top collaborators of Rolf Burghaus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rolf Burghaus. Rolf Burghaus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Morcos, Peter N., Rolf Burghaus, Jonathan Moss, et al.. (2023). Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors. Clinical and Translational Science. 16(7). 1197–1209. 3 indexed citations
3.
Frechen, Sebastian, Ibrahim Ince, André Dallmann, et al.. (2023). Applied physiologically‐based pharmacokinetic modeling to assess uridine diphosphate‐glucuronosyltransferase‐mediated drug–drug interactions for Vericiguat. CPT Pharmacometrics & Systems Pharmacology. 13(1). 79–92. 7 indexed citations
4.
Burghaus, Rolf, et al.. (2023). Opportunities and Challenges for AI-Based Analysis of RWD in Pharmaceutical R&D: A Practical Perspective. KI - Künstliche Intelligenz. 39(1). 7–18. 2 indexed citations
5.
Lippert, Jörg, et al.. (2023). Meta-analysis of preclinical measures of efficacy in immune checkpoint blockade therapies and comparison to clinical efficacy estimates. SHILAP Revista de lepidopterología. 8(1). 1 indexed citations
6.
Schneider, Carolin V., Kai Markus Schneider, Vanessa Baier, et al.. (2022). Early prediction of decompensation (EPOD) score: Non‐invasive determination of cirrhosis decompensation risk. Liver International. 42(3). 640–650. 12 indexed citations
7.
Nagamine, Tasha, et al.. (2022). Data-driven identification of heart failure disease states and progression pathways using electronic health records. Scientific Reports. 12(1). 17871–17871. 13 indexed citations
8.
Frechen, Sebastian, Juri Solodenko, Thomas Wendl, et al.. (2021). A generic framework for the physiologically‐based pharmacokinetic platform qualification of PK‐Sim and its application to predicting cytochrome P450 3A4–mediated drug–drug interactions. CPT Pharmacometrics & Systems Pharmacology. 10(6). 633–644. 26 indexed citations
9.
Meyer, Michaela, Sebastian Schneckener, Katrin Coboeken, et al.. (2021). Leveraging translational approaches for accelerated clinical development of vericiguat. European Heart Journal. 42(Supplement_1). 1 indexed citations
10.
Nagamine, Tasha, et al.. (2020). Multiscale classification of heart failure phenotypes by unsupervised clustering of unstructured electronic medical record data. Scientific Reports. 10(1). 21340–21340. 24 indexed citations
11.
Frechen, Sebastian, Ibrahim Ince, André Dallmann, et al.. (2020). Physiologically-based pharmacokinetic (PBPK) exploration of extrinsic factors influencing vericiguat pharmacokinetics. European Heart Journal. 41(Supplement_2). 3 indexed citations
12.
Lippert, Jörg, Rolf Burghaus, Andrea N. Edginton, et al.. (2019). Open Systems Pharmacology Community—An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences. CPT Pharmacometrics & Systems Pharmacology. 8(12). 878–882. 78 indexed citations
13.
Willmann, Stefan, Kirstin Thelen, Dagmar Kubitza, et al.. (2018). Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study. Thrombosis Journal. 16(1). 32–32. 41 indexed citations
14.
Lippert, Jörg, Rolf Burghaus, Lars Kuepfer, et al.. (2015). Modeling and Simulation of In Vivo Drug Effects. Handbook of experimental pharmacology. 232. 313–329. 5 indexed citations
15.
Burghaus, Rolf, Katrin Coboeken, Christoph Niederalt, et al.. (2014). Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban—an oral, direct Factor Xa inhibitor. Frontiers in Physiology. 5. 417–417. 13 indexed citations
16.
Willmann, Stefan, Corina Becker, Rolf Burghaus, et al.. (2013). Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban. Clinical Pharmacokinetics. 53(1). 89–102. 66 indexed citations
17.
Niederalt, Christoph, Thomas Wendl, Lars Kuepfer, et al.. (2013). Development of a Physiologically Based Computational Kidney Model to Describe the Renal Excretion of Hydrophilic Agents in Rats. Frontiers in Physiology. 3. 494–494. 11 indexed citations
18.
Krauß, Markus, Rolf Burghaus, Jörg Lippert, et al.. (2013). Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification. In Silico Pharmacology. 1(1). 6–6. 43 indexed citations
19.
Thelen, Kirstin, Katrin Coboeken, Stefan Willmann, et al.. (2011). Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, Part 1: Oral solutions. Journal of Pharmaceutical Sciences. 100(12). 5324–5345. 111 indexed citations
20.
Burghaus, Rolf, Katrin Coboeken, Lars Kuepfer, et al.. (2011). Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation. PLoS ONE. 6(4). e17626–e17626. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marylore Chenel Breakdown of academic impact, for papers by Kaori Kadoyama Breakdown of academic impact, for papers by Daniel F. B. Wright Breakdown of academic impact, for papers by Hao Zhu Breakdown of academic impact, for papers by DR Mould Breakdown of academic impact, for papers by Jakob Ribbing Breakdown of academic impact, for papers by Nidal Al‐Huniti Breakdown of academic impact, for papers by Vangelis Karalis Breakdown of academic impact, for papers by MO Karlsson Breakdown of academic impact, for papers by Satjit Brar
Rankless by CCL
2026